Rubicon Research Limited is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. According to F&S, between Fiscals 2023 and 2025, they were the fastest growing Indian pharmaceuticals formulations company with a total revenue CAGR of 75.89% which was over seven times higher than the average (of 11 companies) assessed by F&S. They received 5 Abbreviated New Drug Application ( 'ANDA' ) approvals and 1 New Drug Application ('NDA') approval from the US FDA in the three month period ended June 30, 2025, 3 ANDA approvals in the three month period ended June 30, 2024, 12 ANDA approvals in Fiscal 2025, 14 ANDA approvals in Fiscal 2024 and 12 ANDA approvals in Fiscal 2023. In Fiscal 2025, among the 66 commercialized products ('Commercialized Products') in the US, they held a market share of more than 25% by value for nine products, and in Fiscal 2024 and 2023, they held a market share of more than 25% by value for seven products and two products, respectively. Furthermore, according to F&S, as of July 15, 2025, none of their manufacturing facilities have received an 'Official Action Indicated' ('OAI') status by the US FDA since 2013. As of June 30, 2025, company – directly or through its Subsidiaries – collectively has 72 active ANDAs and nine active NDAs approved by, and one over-the-counter ('OTC') monograph listed with, the US FDA. The Company's portfolio includes 66 Commercialized Products as of March 31, 2025, with a US generic pharmaceutical market size of USD 2,455.7 million, of which the Company contributed USD 195 million in Fiscal 2025. As of June 30, 2025, they have 17 new products awaiting US FDA ANDA approval and 63 product candidates in various stages of development. Company's branded products, i.e. products prescribed by brand name, are marketed through the subsidiary, Validus Pharmaceuticals LLC ('Validus'). Non-branded products, i.e. those for which a prescription with the specific active ingredient (but not a specific brand name) is required, are marketed by the wholly-owned subsidiary AdvaGen Pharma Ltd. ('AdvaGen Pharma') and selectively via third-party distributors. Company engages in the manufacturing and export of formulations spanning a diverse range of dosage forms and therapeutic areas. They also use contract manufacturing organizations ('CMO') in various countries such as India, US and Italy. Of their product portfolio, all ophthalmic products, all injectable products, two nasal spray product, one oral solid product and two oral solution products are presently manufactured for them by third-party CMOs. All products in Validus' portfolio are presently manufactured by third party manufacturers. Company currently hase three manufacturing facilities. The manufacturing facility in Ambernath, Maharashtra, India is 14,250 m2 for manufacturing of oral solid dosages and more recently, for manufacturing of unit-dose, bi-dose, and multi-dose nasal sprays. The second manufacturing facility in Satara, Maharashtra, India is 4,050 m2 for manufacturing of oral liquid dosages. The third manufacturing facility in Pithampur, Madhya Pradesh is 16,000 m2 for manufacturing oral solid dosages for steroids, hormones, and high-potency products, including immunosuppressants and oncology medications in three separate production blocks and topical ointments. This facility has a total plot area of more than 125,000 m2, which would enable them to further expand the manufacturing capabilities in the future. As of June 30, 2025, the manufacturing services have cumulative formulations manufacturing capacity of 10,226.61 million tablets of oral solid dosages per annum, 3,459.08 kilo liters per annum of oral liquid dosages per annum, 4.14 million tubes per annum and 24.83 million bottles/microvials of nasal sprays per annum, on a three-shift basis, subject to product mix. The manufacturing facilities at Ambernath, Satara and Pithampur in India are US FDA inspected. As per financial performance, Rubicon Research Limited has posted total income / net profits of Rs 418.99 Cr / (16.89) Cr (FY23), Rs 872.39 Cr / Rs 91.01 Cr (FY24), Rs 1,296.22 Cr / 134.36 Cr (FY25) and Rs 356.94 Cr / 43.30 Cr (Q1 FY26). So as per previous financials data, company has shown good results. Company has an average EPS of Rs 6.12 and average RoNW of 22.60% for last three fiscals. Issue is priced at a P/BV of 12.59 as per NAV of Rs 38.52/- as on 30.06.25. If we attribute latest earnings of FY24, FY25, TTM and annualised FY26 on equity post issue, then asking price is at a P/E of around 87.79, 59.47, 52.53 and 46.13 respectively. As per RHP, comparison between listed peers is shown in above table. On BRLM's front, Axis Capital Limited, IIFL Capital Services Limited, JM Financial Limited and SBI Capital Markets Limited are associated with this IPO, and have handled 176 IPOs in last three fiscal years. ( As on 09.10.25 ) As per financials, Rubicon Research Limited has shown good results, RoNW is 29% and P/E is 87.79, 59.47, 52.53 and 46.13 respectively as per FY24, FY25, TTM and annualised FY26 earnings. So issue looks aggressively priced when compared with peers, but also company is showing very high growth. Company is a pharmaceutical formulations company, targeting regulated markets and in particular the United States, which is highly competitive business segment. So, we give SUBSCRIBE rating for this IPO. Readers must consult a qualified financial advisor prior to making any actual investment decisions.
✍️ Post a Comment